Smartphone-Enabled, Paper-Based Quantitative Diagnostic Platform Transforms POC Testing
|
By LabMedica International staff writers Posted on 08 Oct 2024 |

Point-of-care diagnostics are crucial for public health, offering rapid, on-site testing that enables prompt diagnosis and treatment. This is especially valuable in remote or underserved regions where access to laboratory resources is limited. By enabling immediate clinical decisions, point-of-care testing can alleviate strain on healthcare systems and enhance patient outcomes. Now, a new study has demonstrated the effectiveness of a smartphone-enabled, paper-based quantitative diagnostic platform, which improves point-of-care diagnostics by delivering enhanced accuracy, real-time data, and broader accessibility for fast and reliable testing.
The study focused on HueDx’s (Pennsylvania, PA, USA) innovative platform, which comprises HueTools and HueLab. HueDx’s HueTools are artificial intelligence (AI) tools that shorten assay development from years to months while its HueLab customizable cartridge and app, create a portable testing solution that eliminates the need for a traditional lab. This research represents a significant breakthrough in colorimetric diagnostic methods, overcoming past challenges in achieving accurate and consistent results in clinical chemistry at the point of care without requiring additional hardware. The incorporation of smartphone technology enhances these capabilities, allowing for the quantification of previously qualitative assays and enabling real-time data collection and analysis. This will expand point-of-care testing to more providers, including at-home testing, delivering quantitative and actionable results.
The study found that the color correction system restored images to near-perfect consistency, independent of original illumination conditions. In precision testing, the coefficient of variation was nearly twice as high without the color correction. Additionally, limits of blank, detection, and quantification were significantly improved using the HueDx pipeline. The research also demonstrated the platform's effectiveness in calibrating and quantifying a paper-based total protein assay, illustrating its potential for use in point-of-care testing across diverse medical settings.
“The HueDx color correction system represents a major leap forward in diagnostic technology, allowing for accurate and reliable testing in real-world settings,” said Dr. Nidhi Menon, Head of R&D, at HueDx, Inc. “We’re dedicated to enhancing health outcomes with innovative solutions, and our work truly reflects that commitment, setting the stage for the future of smartphone-enabled diagnostics.”
Related Links:
HueDx
Latest Clinical Chem. News
- Chemical Imaging Probe Could Track and Treat Prostate Cancer
- Mismatch Between Two Common Kidney Function Tests Indicates Serious Health Problems
- VOCs Show Promise for Early Multi-Cancer Detection
- Portable Raman Spectroscopy Offers Cost-Effective Kidney Disease Diagnosis at POC
- Gold Nanoparticles to Improve Accuracy of Ovarian Cancer Diagnosis
- Simultaneous Cell Isolation Technology Improves Cancer Diagnostic Accuracy
- Simple Non-Invasive Hair-Based Test Could Speed ALS Diagnosis
- Paper Strip Saliva Test Detects Elevated Uric Acid Levels Without Blood Draws
- Prostate Cancer Markers Based on Chemical Make-Up of Calcifications to Speed Up Detection
- Breath Test Could Help Detect Blood Cancers
- ML-Powered Gas Sensors to Detect Pathogens and AMR at POC
- Saliva-Based Cancer Detection Technology Eliminates Need for Complex Sample Preparation
- Skin Swabs Could Detect Parkinson’s Years Before Symptoms Appear
- New Clinical Chemistry Analyzer Designed to Meet Growing Demands of Modern Labs

- New Reference Measurement Procedure Standardizes Nucleic Acid Amplification Test Results
- Pen-Like Tool Quickly and Non-Invasively Detects Opioids from Skin
Channels
Clinical Chemistry
view channel
Chemical Imaging Probe Could Track and Treat Prostate Cancer
Prostate cancer remains a leading cause of illness and death among men, with many patients eventually developing resistance to standard hormone-blocking therapies. These drugs often lose effectiveness... Read more
Mismatch Between Two Common Kidney Function Tests Indicates Serious Health Problems
Creatinine has long been the standard for measuring kidney filtration, while cystatin C — a protein produced by all human cells — has been recommended as a complementary marker because it is influenced... Read moreMolecular Diagnostics
view channel
New Serum Marker-Editing Strategy to Improve Diagnosis of Neurological Diseases
Tracking gene-expression changes in the brain is crucial for understanding neurological diseases, yet current monitoring tools are invasive or unable to capture subtle activity shifts over time.... Read more
World’s First Genetic Type 1 Diabetes Risk Test Enables Early Detection
Type 1 Diabetes (T1D) affects more than eight million people worldwide, with numbers expected to rise sharply. While most cases are genetically driven, only one in ten patients has a family history, making... Read moreHematology
view channel
Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
Assessing disease severity in sickle cell disease (SCD) remains challenging, especially when trying to predict hemolysis, vascular injury, and risk of complications such as vaso-occlusive crises.... Read more
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read moreImmunology
view channel
Gene Signature Test Predicts Response to Key Breast Cancer Treatment
DK4/6 inhibitors paired with hormone therapy have become a cornerstone treatment for advanced HR+/HER2– breast cancer, slowing tumor growth by blocking key proteins that drive cell division.... Read more
Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
Ductal carcinoma in situ (DCIS) accounts for about a quarter of all breast cancer cases and generally carries a good prognosis. This non-invasive form of the disease may or may not become life-threatening.... Read moreMicrobiology
view channelRapid POC Tuberculosis Test Provides Results Within 15 Minutes
Tuberculosis remains one of the world’s deadliest infectious diseases, and reducing new cases depends on identifying individuals with latent infection before it progresses. Current diagnostic tools often... Read more
Rapid Assay Identifies Bloodstream Infection Pathogens Directly from Patient Samples
Bloodstream infections in sepsis progress quickly and demand rapid, precise diagnosis. Current blood-culture methods often take one to five days to identify the pathogen, leaving clinicians to treat blindly... Read morePathology
view channelAI Tool Outperforms Doctors in Spotting Blood Cell Abnormalities
Diagnosing blood disorders depends on recognizing subtle abnormalities in cell size, shape, and structure, yet this process is slow, subjective, and requires years of expert training. Even specialists... Read more
AI Tool Rapidly Analyzes Complex Cancer Images for Personalized Treatment
Complex digital biopsy images that typically take an expert pathologist up to 20 minutes to assess can now be analyzed in about one minute using a new artificial intelligence (AI) tool. The technology... Read moreTechnology
view channel
AI Saliva Sensor Enables Early Detection of Head and Neck Cancer
Early detection of head and neck cancer remains difficult because the disease produces few or no symptoms in its earliest stages, and lesions often lie deep within the head or neck, where biopsy or endoscopy... Read more
AI-Powered Biosensor Technology to Enable Breath Test for Lung Cancer Detection
Detecting lung cancer early remains one of the biggest challenges in oncology, largely because current tools are invasive, expensive, or unable to identify the disease in its earliest phases.... Read moreIndustry
view channel
Abbott Acquires Cancer-Screening Company Exact Sciences
Abbott (Abbott Park, IL, USA) has entered into a definitive agreement to acquire Exact Sciences (Madison, WI, USA), enabling it to enter and lead in fast-growing cancer diagnostics segments.... Read more








